Person:
TİGEN, ELİF

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

TİGEN

First Name

ELİF

Name

Filters

2011 - 201962020 - 202315
Reset filters

Settings

Has files: true ×

Search Results

Now showing 1 - 10 of 22
  • Thumbnail Image
    PublicationOpen Access
    A rare Case of otitis media-associated polymicrobial anaerobic meningitis and brain abscess
    (2021-12-01) ERTÜRK ŞENGEL, BUKET; TİGEN, ELİF; OLUÇ, YUSUF; ÜLGER, NURVER; KORTEN, VOLKAN; ERTÜRK ŞENGEL B., TİGEN E., YILDIZ F., OLUÇ Y., ÜLGER N., KORTEN V.
    Otitis media-associated complications are widespread when it is not treated with appropriate antimicrobial treatment. Meningitis and brain abscess are the most reported intracranial complications of otitis media, usually caused by the direct spread of organisms from the contagious site. While anaerobic microorganisms are well-known in brain abscesses, they are not common in meningitis. When the clinical history and pathogenesis of otitis mediaassociated meningitis are combined, special methods to identify and cover anaerobic pathogens should be considered
  • Thumbnail Image
    PublicationOpen Access
    Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey
    (BMC, 2016-12) TİGEN, ELİF; Karacaer, Zehra; Cakir, Banu; Erdem, Hakan; Ugurlu, Kenan; Durmus, Gul; Ince, Nevin Koc; Ozturk, Cinar; Hasbun, Rodrigo; Batirel, Ayse; Yilmaz, Esmeray Mutlu; Bozkurt, Ilkay; Sunbul, Mustafa; Aynioglu, Aynur; Atilla, Aynur; Erbay, Ayse; Inci, Ayse; Kader, Cigdem; Tigen, Elif Tukenmez; Karaahmetoglu, Gokhan; Coskuner, Seher Ayten; Dik, Ebru; Tarakci, Huseyin; Tosun, Selma; Korkmaz, Fatime; Kolgelier, Servet; Karadag, Fatma Yilmaz; Erol, Serpil; Turker, Kamuran; Necan, Ceyda; Sahin, Ahmet Melih; Ergen, Pinar; Iskender, Gulsen; Korkmaz, Pinar; Eroglu, Esma Gulesen; Durdu, Yasemin; Ulug, Mehmet; Deniz, Suna Secil; Koc, Filiz; Alpat, Saygin Nayman; Oztoprak, Nefise; Evirgen, Omer; Sozen, Hamdi; Dogan, Mustafa; Kaya, Selcuk; Kaya, Safak; Altindis, Mustafa; Aslan, Emel; Tekin, Recep; Sezer, Busra Ergut; Ozdemir, Kevser; Ersoz, Gulden; Sahin, Ahmet; Celik, Ilhami; Aydin, Emsal; Bastug, Aliye; Harman, Rezan; Ozkaya, Hacer Deniz; Parlak, Emine; Yavuz, Ilknur; Sacar, Suzan; Comoglu, Senol; Yenilmez, Ercan; Sirmatel, Fatma; Balkan, Ilker Inanc; Alpay, Yesim; Hatipoglu, Mustafa; Denk, Affan; Senol, Gunes; Bitirgen, Mehmet; Geyik, Mehmet Faruk; Guner, Rahmet; Kadanali, Ayten; Karakas, Ahmet; Namiduru, Mustafa; Udurgucu, Hatice; Boluktas, Rukiye Pinar; Karagoz, Ergenekon; Ormeci, Necati
    Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.
  • Thumbnail Image
    PublicationOpen Access
    Antibiotic overconsumption and resistance in Turkey
    (ELSEVIER SCI LTD) TİGEN, ELİF; Isler, B.; Keske, S.; Aksoy, M.; Azap, O. K.; Yilmaz, M.; Yavuz, S. S.; Aygun, G.; Tigen, E.; Akalin, H.; Azap, A.; Ergonul, O.
  • Thumbnail Image
    PublicationOpen Access
    Drug eruption: A mimicker of Coronavirus disease-2019 rash
    (2022-01-01) ERGUN, SAFİYE ATLAS TÜLİN; SEVEN, SEDA; SEÇKİN GENÇOSMANOĞLU, DİLEK; TİGEN, ELİF; AKTAŞ, MERYEM; ERGUN S. A. T., Ergenc I., SEVEN S., SEÇKİN GENÇOSMANOĞLU D., CÖMERT ÖZER E., AKTAŞ M., TİGEN E.
    Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections can be associated with several cutaneous lesions, among which maculopapular rash is the most common. A maculopapular rash can also be induced by medications used for Coronavirus disease-2019 (COVID-19) treatment. The distinction between viral rash and drug eruption may be difficult especially in case of several medication use for COVID-19. Thus, this study aimed to describe cutaneous manifestations in six patients with COVID-19 and highlight dues for distinguishing SARS-CoV-2-related rash and drug eruption. Between March and June 2020, 1,492 patients were hospitalized for COVID-19 and treated with hydroxychloroquine in Marmara University Hospital. Among them, six cases were consulted for possible COVID-19-related rash or drug reaction. Hydroxychloroquine was given as monotherapy in one patient. All six patients developed an erythematous, symmetrical, and maculopapular eruption that mainly affected the trunk, axilla, and genitocrural region, 5-21 days after the onset of COVID-19 symptoms. Five patients developed rash in 4-11 days after treatment completion. Pruritus was severe. All were treated with topical corticosteroids and oral antihistamines, which provided partial relief. The resolution of the eruption was typically slow, which took a few weeks. A long period between the COVID-19 symptoms and the eruption, as well as slow recovery, is in favor of drug eruption. The effects of co-existent viral infection, a well-known promoting drug eruption factor, in facilitating adverse drug reaction in patients with COVID-19 needs further observations and research.
  • Thumbnail Image
    PublicationOpen Access
    Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience
    (2022-02) TİGEN, ELİF; Kaya, Burcu; Barutcu Atas, Dilek; Tukenmez Tigen, Elif; Asicioglu, Ebru; Arikan, Hakki; Tuglular, Serhan; Velioglu, Arzu
  • Thumbnail Image
    PublicationOpen Access
    Marmara Üniversitesi Pendik Eğitim ve ID_x000D_ Araştırma Hastanesi’nde 2014-2018 Yılları_x000D_ Arasındaki Kronik Hepatit C Prevalansı,_x000D_ Genotip Dağılımı ve Tedavi Yanıtları
    (2020) ERTÜRK ŞENGEL, BUKET; Betül ERTÜRK ŞENGEL;Tuğçe BAŞARI;Elif TÜKENMEZ TİGEN;Rabia CAN SARINOĞLU;Barış CAN;ULUHAN SİLİ;Volkan KORTEN
    Hepatit C dünyada yaygın olarak görülen ve mortaliteye neden olabilen ciddi bir hastalıktır.Bu çalışmada Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi’nebaşvuran hastalarda anti-HCV seropozitiflik sıklığının ve kronik viral hepatit C (HCV)tanısı konarak tedavi verilen hastaların genotip dağılımları ile tedavi başarılarınındeğerlendirilmesi amaçlanmıştır. Çalışmada retrospektif olarak Ocak 2014-Aralık 2018tarihleri arasında anti-HCV istemi yapılan serum örnekleri taranmıştır. Reaktif bulunanörneklerin HCV RNA pozitiflikleri ile genotip dağılımları ve kronik HCV tanısı ile tedaviverilen hastaların kalıcı viral yanıt başarı oranları değerlendirilmiştir. Total 76,413 hastadan100,100 serum örneğinde anti-HCV istemi yapılmış ve 1,808 (% 2,36) hastadapozitif bulunmuştur. Bu hastaların 1,286’sında (% 71) HCV RNA bakılmış ve 291 (% 23)hastada pozitif saptanmıştır. HCV RNA tespit edilen hastalarda 129’una (% 44) hastanemizdekronik HCV tanısı ile tedavi verilmiştir. En sık genotip 1b saptanmış olup, tedavisonrası 24’üncü haftada kalıcı viral yanıt hastaların % 87’sinde elde edilmiştir. Sonuçolarak antiviral tedavi ile virolojik başarı oranları yüz güldürücü olsa da halen tanı vetedavi alması gereken ancak tespit edilemeyen hasta sayısı da oldukça yüksektir.
  • Thumbnail Image
    PublicationOpen Access
    Unusual causes of peritonitis in a peritoneal dialysis patient: Alcaligenes faecalis and Pantoea agglomerans
    (BMC, 2011) VELİOĞLU, ARZU; Kahveci, Arzu; Asicioglu, Ebru; Tigen, Elif; Ari, Elif; Arikan, Hakki; Odabasi, Zekaver; Ozener, Cetin
    An 87-year-old female who was undergoing peritoneal dialysis presented with peritonitis caused by Alcaligenes faecalis and Pantoea agglomerans in consecutive years. With the following report we discuss the importance of these unusual microorganisms in peritoneal dialysis patients.
  • Thumbnail Image
    PublicationOpen Access
    The Impact of C Reactive Protein in _x000D_ Prediction of the Outcome in Infective _x000D_ Endocarditis
    (2021-04-30) TİGEN, ELİF; Serap ŞİMŞEK YAVUZ;Sibel DOĞAN KAYA;Denef BERZEG DENİZ;Elif TÜKENMEZ TİGEN;Serpil ÖZTÜRK;Şirin MENEKŞE;Mutlu Şeyda ÖCALMAZ;Seniha BAŞARAN;Ayfer ŞENSOY;Yeşim UYGUN KIZMAZ;Ezgi ÖZBEK;Haluk ERAKSOY
    Objective: A simple and widely available test is needed to monitor the response to the treatment and predict adverse outcomes in patients with infective endocarditis (IE). We aimed to detect the role of C-reactive protein (CRP) level in the prognosis of IE.Materials and Methods: The patients diagnosed as probable or definite IE between 2015 and 2016 from five medical centers were included in the study. Clinical and laboratory features of the patients recorded on previously prepared forms retrospectively. Comparison of CRP levels between survived and dead patients were made by repeated-measures variance analysis. Receiver operating characteristic (ROC) curves at baseline, the first, second, third and fourth week of antimicrobial treatment were constructed to explain the ability of CRP level to predict mortality. Multivariate analysis was performed to predict the risk factors for mortality. Results: In total, 111 cases of IE were included. Serum CRP levels were higher in patients with mortality at every measurement. Comparing baseline CRP, lower than a double or triple decrease of serum CRP level at the third or fourth week of treatment or any increase under treatment were related to mortality. According to the ROC curve analysis, the highest overall accuracy in death prediction was at the fourth week CRP level (c=0.74); the CRP level of ≥50 mg/L was 86% sensitive and 78% specific to predict mortality. The presence of chronic renal failure (OR 14.386) and the fourth week CRP level (OR 1.016) were independent risk factors in terms of mortality. Conclusion: Being an easily performed and widely available test, CRP is a useful tool to follow up the response to the treatment and predict outcome among patients with IE. In the fourth week of treatment, a CRP level of ≥50 mg/L should be regarded as an alarming sign of poor outcome and should lead to investigation and appropriate management of complications.
  • Thumbnail Image
    PublicationOpen Access
    The risk factors of colistin methanesulfonate associated nephrotoxicity
    (WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2016-06) TİGEN, ELİF; Tigen, Elif Tukenmez; Koltka, E. Nursen; Dogru, Arzu; Gura, Melek; Vahabaoglu, Haluk
    Purpose: The risk factors of colistin methanesulfonate (CMS) associated nephrotoxicity are important. Our study attempts look into the prevalence of CMS-associated nephrotoxicity in Intensive Care Units (ICUs), and related risk factors. Materials and Methods: The study was conducted between September 2010 and April 2012 on 55 patients who underwent CMS treatment. Nephrotoxicity risk was defined based on the Risk Injury Failure Loss End-stage kidney disease criteria. Results: Fifty-five patients included in the study. A total of 22 (40%) patients developed nephrotoxicity. The correlation was detected between nephrotoxicity and patients over 65 with a high Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II score. APACHE II score was revealed an independent risk factor for nephrotoxicity. Conclusion: Advanced age and a high APACHE II score are significant risk factors in the development of nephrotoxicity at ICUs following CMS use. Patient selection and close monitoring are critical when starting CMS treatment.
  • Thumbnail Image
    PublicationOpen Access
    Cryptococcus meningitis presented with multiple cerebral infarcts in an immunocompetent patient
    (ELSEVIER SCI LTD, 2021) ERTÜRK ŞENGEL, BUKET; Sengel, Buket Erturk; Tigen, Elif Tukenmez; Sarinoglu, Rabia Can; Midi, Ipek; Cerikcioglu, Nilgun; Odabasi, Zekaver
    Cryptococcus neoformans is generally observed with immunosuppressive conditions. Rarely, it may be seen in immunocompetent individuals and presented with non-specific conditions. We described an immunocompetent case of cryptococcal meningitis presented with multiple cerebral infarcts. Despite the late diagnosis and emergence of hydrocephalus during treatment, the patient was recovered without any sequelae. In immunocompetent patients, the conventional diagnostics tests may be negative because of the low fungal load. If it is available, the Biofire FilmArray meningitis panel has high sensitivity and specificity for diagnosis. (C) 2021 The Authors. Published by Elsevier Ltd.